Company intelligence / Profile preview

BresoTEC

Toronto, Ontario, Canadaca.linkedin.com ↗

Ownership: Private
Development stage: Other

Overview

The company's lead product, BresoDX1, has demonstrated strong clinical validation for at-home diagnosis of moderate to severe sleep apnea. In a pivotal study with 164 subjects comparing the device to in-lab polysomnography (PSG), sensitivity was 88.5% and specificity was 84.9% for detecting moderate-to-severe sleep apnea using established criteria. The product received FDA clearance in December 2022 and commercial launch began in the US market in Q3 2023.

Therapeutic areas: Pulmonology
Modalities: Device (diagnostic medical device)
Industry: Physiological Monitoring

Partnerships

University Health Network/Toronto Rehabilitation Institute (technology origin/licensing)

Beyond the preview

Go deeper on BresoTEC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BresoTEC.

Explore the full profile